Insulin Human
- Insulin Human
- Human Insulin
- Insulin (human)
- Myxredlin
- Humulin
- Insulin Human
- Human Insulin
- Insulin (human)
- Myxredlin
- Humulin
- 1Y17CTI5SR
- 234-279-7
- High molecular weight insulin human
- Insulin Human Regular
- Insulin human regular (rDNA)
- Insulin human, rDNA origin
- Insulin recombinant purified human
- Insulin, human
- Regular Insulin, human
- A10AB01
- A10AC01
- A10AD01
- A10AE01
- A10AF01
- CAPSULIN
- DTXSID7040499
- EXUBERA (INHALED INSULIN HUMAN)
- HIGH MOLECULAR WEIGHT INSULIN HUMAN (USP-RS)
- HUMULIN BR
- HUMULIN R KWIKPEN
- Humalog 70/30
- Humulin R U-100
- Humulin R U-500
- Humulin70/30
- Humulin70/30 KwikPen
- HumulinN
- HumulinR
- HumulinR U-500
- HumulinR U-500 KwikPen
- INSULIN HUMAN (USP MONOGRAPH)
- INSULIN HUMAN (USP-RS)
- INSULIN HUMAN LENTE
- INSULIN HUMAN NPH
- INSULIN HUMAN RDNA
- INSULIN HUMAN SEMISYNTHETIC
- INSULIN INJECTION HUMAN BIOSYNTHETIC
- INSULIN RECONBINANET HUMAN
- INSULIN SEMI SYNTHETIC HUMAN
- INSULIN SEMISYNTHETIC HUMAN
- INSULIN, HUMAN (EP MONOGRAPH)
- INSULIN,LENTE,HUMAN/RDNA
- INSULIN,LENTE,HUMAN/SEMISYNTHETIC
- INSULIN,NPH,HUMAN/RDNA
- INSULIN,NPH,HUMAN/SEMISYNTHETIC
- INSULIN,REGULAR,HUMAN BUFFERED
- INSULIN,REGULAR,HUMAN/RDNA
- INSULIN,REGULAR,HUMAN/SEMISYNTHETIC
- INSULIN,ULTRALENTE,HUMAN
- INSULIN,ULTRALENTE,HUMAN/RDNA
- Insulin human (rDNA origin)
- Insulin recombinant
- Insulina regular
- Novolin70/30
- NovolinN
- NovolinR
- RPROT P01308 (INS_HUMAN) INSULIN (HGI519)
- VIATAB
- human insulin (rDNA)
- insulin (recombinant)
- insulin human, for immunoassay
- insulina umana
- Epinephrine; insulin human; sus scrofa pituitary gland; sus scrofa thyroid (component of)
- Herring sperm dna; insulin human; lycopodium clavatum spore; pancrelipase; phosphoric acid; radium bromide; uranyl nitrate hexahydrate (component of)
- 7-Keto-dehydroepiandrosterone; adenosine triphosphate disodium; echinacea, unspecified; gamboge; graphite; insulin human; lactic acid, L-; methylcobalamin; phytolacca americana root; pork kidney; pork liver; proteus vulgaris; strychnos nux-vomica seed; sus scrofa hypothalamus; sus scrofa pancreas; vincetoxicum hirundinaria root (component of)
- Chionanthus virginicus root bark; chromium; chromium picolinate; cinnamon; fenugreek seed; gymnema sylvestre leaf; herring sperm dna; hexaplex trunculus hypobranchial gland juice; insulin human; lycopodium clavatum spore; phosphoric acid; phosphorus; pork liver; rhus aromatica root bark; silver nitrate; sulfur; sus scrofa pancreas; syzygium cumini seed; uranyl nitrate hexahydrate; vanadium; zinc (component of)
- Acetic acid; arsenic trioxide; aspirin; benzoic acid; benzyl alcohol; boric acid; chlorine; corticotropin; cortisone acetate; estrone; eugenol; glycerin; insulin human; isopropyl palmitate; kerosene; lactic acid, DL-; lead; lithium carbonate; nitric acid; nitroglycerin; petrolatum; phenylbutazone; phosphoric acid; phosphorus; phytolacca americana root; potassium sorbate; resorcinol; salicylic acid; sorbitol; stearyl alcohol; strychnos nux-vomica seed; taraxacum officinale; thyroid, porcine; xylitol (component of)
- Acetaldehyde; adenosine triphosphate disodium; alloxan; anhydrous citric acid; ascorbic acid; barium oxalate; berberis vulgaris root bark; fumaric acid; gymnema sylvestre leaf; human breast tumor cell; insulin human; insulin pork; lactic acid, L-; lycopodium clavatum spore; momordica balsamina immature fruit; nadide; pantothenic acid; phlorizin; phosphoric acid; phosphorus; pork liver; prasterone; pyridoxine hydrochloride; riboflavin; salmonella enterica subsp. enterica serovar enteritidis; sus scrofa pancreas; syzygium cumini seed; thiamine hydrochloride; thioctic acid; trigonella foenum-graecum whole (component of)
- Acetaldehyde; adenosine triphosphate disodium; alloxan; anhydrous citric acid; ascorbic acid; barium oxalosuccinate; berberis vulgaris root bark; fumaric acid; gymnema sylvestre leaf; human breast tumor cell; insulin human; insulin pork; lactic acid, L-; lycopodium clavatum spore; momordica balsamina immature fruit; nadide; pantothenic acid; phlorizin; phosphoric acid; phosphorus; pork liver; prasterone; pyridoxine hydrochloride; riboflavin; salmonella enterica subsp. enterica serovar enteritidis; sus scrofa pancreas; syzygium cumini seed; thiamine hydrochloride; thioctic acid; trigonella foenum-graecum whole (component of)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AE - Insulins and analogues for injection, long-acting
A10AE01 - Insulin (human)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AF - Insulins and analogues for inhalation
A10AF01 - Insulin (human)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AB - Insulins and analogues for injection, fast-acting
A10AB01 - Insulin (human)
Not Classified
Reported as not meeting GHS hazard criteria by 1 of 1 companies. For more detailed information, please visit ECHA C&L website.
◉ Summary of Use during Lactation
Mothers with diabetes using insulin may nurse their infants. Exogenous insulin is excreted into breastmilk, including newer biosynthetic insulins (e.g., aspart, deglutec, detemir, glargine glulisine, lispro). Even direct administration of recombinant insulin orally to preterm infants is safe. Insulin is a normal component of breastmilk and may decrease the risk of type 1 diabetes in breastfed infants. Women taking insulin for type 2 diabetes have higher milk insulin levels than those controlled with diet alone.
Insulin requirements are reduced postpartum in women with type 1 diabetes, although postpartum insulin requirements do not significantly differ between breastfeeding and non-breastfeeding women. In general, insulin requirements are 30% to 50% lower than prepregnancy dosages immediately postpartum. Then the insulin requirements during breastfeeding average 21% lower than prepregnancy dosages, but there is wide variation. In one study, insulin requirements were lower than prepregnancy dosage only during the first week postpartum: 54% of prepregnancy dosage on day 2 and 73% on day 3 postpartum. On day 7 postpartum, insulin dosage returned to prepregnancy requirements. Another study found that dosage requirements did not return to normal for up to 6 weeks in some mothers. A third study found that at 4 months postpartum, patients with type 1 diabetes who exclusively breastfed had an average of 13% lower (range -52% to +40%) insulin requirement than their prepregnancy requirement. A retrospective case-control study found a 34% decrease in postpartum insulin requirement compare to preconception values. There was a nonsignificant trend towards lower requirements in exclusively breastfeeding mothers compared to partial or full formula feeding. A small study found that mothers on insulin pumps were found to have an average basal insulin rates 14% lower and carbohydrate-to-insulin ratios were 10% higher than pre-pregnancy settings. Breastfeeding appears to improve glucose postpartum glucose tolerance in mothers with gestational diabetes mellitus and in normal women.
A small, well-controlled study of women with type 1 diabetes mellitus using continuous subcutaneous insulin found that the average basal insulin requirement in women with type 1 diabetes who breastfed was 0.21 units/kg daily and the total insulin requirement was 0.56 units/kg daily. In similar women who did not breastfeed, the basal insulin requirement was 0.33 units/kg daily and the total insulin requirement was 0.75 units/kg daily. The 36% lower basal insulin requirement was thought to be caused by glucose use for milk production.
Lactation onset occurs later in patients with type 1 diabetes than in women without diabetes, with a greater delay in mothers with poor glucose control. Mothers with type 1 diabetes also discontinue nursing at a higher rate during the first week postpartum. Women with any form of diabetes during pregnancy had more problems with low milk supply than women without diabetes. Once established, lactation persists as long in mothers with diabetes as in mothers without diabetes. However, as in women without diabetes, smoking has a strong negative impact on lactation among mothers with type 1 diabetes. Other factors that have been identified as causes of shorter duration of breastfeeding among type 1 diabetic patients are more frequent caesarean sections and earlier delivery. Among patients with gestational diabetes, those treated with insulin have a delayed onset of lactogenesis II and lower exclusive breastfeeding rates compared to those not treated with insulin.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date. Insulin in breastmilk is thought to be necessary for intestinal maturation of the infant and may help decrease the risk of contracting type 1 diabetes in breastfed infants.
◉ Effects on Lactation and Breastmilk
Proper insulin levels are necessary for lactation. Good glycemic control enhances maternal serum and milk prolactin concentrations and decreases the delay in the establishment of lactation that can occur in mothers with type 1 diabetes.
One-hundred two of 107 consecutive mothers with type 1 diabetes mellitus who delivered were followed at a Danish hospital. Mothers were given prenatal information on breastfeeding and were offered postnatal counseling by a nurse on the benefits of breastfeeding. All infants were admitted to the neonatal intensive care unit at about 2 hours of age for the following 24 hours. When possible, mothers either breastfed or pumped milk for their infants during this time. Mothers were contacted at 5 days and 4 months postpartum to determine their breastfeeding status. The rates of initiation of exclusive and nonexclusive breastfeeding and exclusive formula feeding and the rates at 4 months postpartum were no different from those of the Danish population.
Eight hundred eighty-three women with gestational diabetes were interviewed at 6 to 9 weeks postpartum. Those who had been treated with insulin more frequently reported having a delayed onset of lactogenesis II (>72 hours) postpartum than those not treated with insulin, independent of other maternal risk factors. The odds ratio of having delayed lactogenesis II was 3.1 among insulin-treated mothers compared to mothers with gestational diabetes who did not receive insulin.
A small, controlled trial of women with gestational diabetes compared those treated with insulin to women treated with diet and exercise. Those treated with insulin had a lower rate of exclusive breastfeeding than those treated with diet and exercise (57% vs 81%).
- USRE37872
- CA2183577
- CA2253393
- US7291132
- US6257233
- US6546929
- US6685967
- US6582728
- US8912193
- US7648960
- US6652885
- US8258095
- US8778403
- US6444226
- US7943572
- US8119593
- US7943178
- US8889099
- US8623817
- US8389470
- US9192675
- US8215300
- US8146588
- US8950397
- US8485180
- US9283193
- US8636001
- US8424518
- US8551528
- US7464706
- US8729019
- US7305986
- US8499757
- US8156936
- US8734845
- US8227409
- US9393372
- US9339615
- US9511198
- US9597374
- US9358352
- US9446133
- US9662461
- US9717689
- US9943571
- US10046031
- US10201672
- US10342938
- US10500159
- PubChem Reference CollectionInsulin Humanhttps://pubchem.ncbi.nlm.nih.gov/substance/481107246
- PubChem
- ChemIDplusInsulin human [USAN:USP:INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0011061680
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useInsulin humanhttps://www.drugbank.ca/drugs/DB00030
- EPA DSSToxHuman insulinhttps://comptox.epa.gov/dashboard/DTXSID7040499
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeInsulin (human) (EC: 234-279-7)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/82304
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- DailyMed
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeInsuman (EMEA/H/C/000201)https://www.ema.europa.eu/en/medicines/human/EPAR/insumanInsulatard (EMEA/H/C/000441)https://www.ema.europa.eu/en/medicines/human/EPAR/insulatardProtaphane (EMEA/H/C/000442)https://www.ema.europa.eu/en/medicines/human/EPAR/protaphaneActrapid (EMEA/H/C/000424)https://www.ema.europa.eu/en/medicines/human/EPAR/actrapidActraphane (EMEA/H/C/000427)https://www.ema.europa.eu/en/medicines/human/EPAR/actraphaneMixtard (EMEA/H/C/000428)https://www.ema.europa.eu/en/medicines/human/EPAR/mixtardProZinc (EMEA/V/C/002634)https://www.ema.europa.eu/en/medicines/veterinary/EPAR/prozincInsulin Human Winthrop (EMEA/H/C/000761)https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-human-winthropSolumarv (EMEA/H/C/003858)https://www.ema.europa.eu/en/medicines/human/EPAR/solumarv-0Velosulin (EMEA/H/C/000423)https://www.ema.europa.eu/en/medicines/human/EPAR/velosulinExubera (EMEA/H/C/000588)https://www.ema.europa.eu/en/medicines/human/EPAR/exuberaMonotard (EMEA/H/C/000440)https://www.ema.europa.eu/en/medicines/human/EPAR/monotardUltratard (EMEA/H/C/000439)https://www.ema.europa.eu/en/medicines/human/EPAR/ultratard
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingINSULIN HUMANhttps://www.accessdata.fda.gov/scripts/cder/daf/
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/Insulin (human)https://www.whocc.no/atc_ddd_index/?code=A10AE01Insulin (human)https://www.whocc.no/atc_ddd_index/?code=A10AF01Insulin (human)https://www.whocc.no/atc_ddd_index/?code=A10AB01Insulin (human)https://www.whocc.no/atc_ddd_index/?code=A10AC01Insulin (human)https://www.whocc.no/atc_ddd_index/?code=A10AD01
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- FDA Purple Book
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlinsulin, regular, humanhttps://rxnav.nlm.nih.gov/id/rxnorm/253182